FDA, USP spar over biologics monographs

FDA has thrown its support behind a proposal in President Donald Trump's FY20 budget that would exclude biologics and biosimilars from meeting monograph standards established by the U.S. Pharmacopeia for small molecules, a measure

Read the full 340 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE